Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data

Ellen M.Lavoie Smith, Tanima Banerjee, James J. Yang, Celia M. Bridges, Paola Alberti, Jeff A Sloan, Charles Lawrence Loprinzi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background No criterion-standard patient-reported outcome measure of chemotherapy-induced peripheral neuropathy (CIPN) exists. Objectives The aims of this study were to reevaluate the sensitivity, reliability, and validity of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN (QLQ-CIPN20) measure and suggest possible revisions that could strengthen it. Methods Cross-sectional QLQ-CIPN20 data from 8 European countries (n = 271) were pooled with data from 4 North American multisite CIPN intervention trials (n = 884). The combined sample (N = 1155) included patients with varied cancer diagnoses who had received neurotoxic chemotherapy. Item score ranges, Cronbach's α, and exploratory factor analysis were used to evaluate sensitivity, internal consistency, and structural validity. Results Individual item mean scores ranged from 1.21 to 2.34 (SD range, 0.55-1.17). All item scores encompassed the entire 1 to 4 range. We recommend that 4 items be removed because of low item-item score correlations (r < 0.30). On the basis of the remaining 16 items, 88% of the variance was explained by 2 factors whose Cronbach's α coefficients were.90 and.85. However, items lacked conceptual alignment with previously published factor structures. Conclusion Using a large, diverse sample of European and North American participants, the reduced 16-item QLQ-CIPN20 is sensitive and internally consistent. However, factor analysis results revealed an unstable factor structure. Implications for Practice The use of a reliable, valid, and sensitive criterion-standard QLQ-CIPN20 variant in clinical practice settings could improve function, quality of life, and CIPN symptom control by facilitating patient reporting and thereby clinician awareness of this underrecognized consequence of cancer therapy.

Original languageEnglish (US)
Pages (from-to)179-189
Number of pages11
JournalCancer Nursing
Volume42
Issue number3
DOIs
StatePublished - May 1 2019

Fingerprint

Peripheral Nervous System Diseases
Psychometrics
Quality of Life
Outcome Assessment (Health Care)
Clinical Trials
Drug Therapy
Statistical Factor Analysis
Reproducibility of Results
Neoplasms
Surveys and Questionnaires

Keywords

  • Chemotherapy-induced peripheral neuropathy (CIPN)
  • QLQ-CIPN20
  • Reliability
  • Sensitivity
  • Validity

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)

Cite this

@article{d15d77f76c4346df9256cdd2cf3806b3,
title = "Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data",
abstract = "Background No criterion-standard patient-reported outcome measure of chemotherapy-induced peripheral neuropathy (CIPN) exists. Objectives The aims of this study were to reevaluate the sensitivity, reliability, and validity of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN (QLQ-CIPN20) measure and suggest possible revisions that could strengthen it. Methods Cross-sectional QLQ-CIPN20 data from 8 European countries (n = 271) were pooled with data from 4 North American multisite CIPN intervention trials (n = 884). The combined sample (N = 1155) included patients with varied cancer diagnoses who had received neurotoxic chemotherapy. Item score ranges, Cronbach's α, and exploratory factor analysis were used to evaluate sensitivity, internal consistency, and structural validity. Results Individual item mean scores ranged from 1.21 to 2.34 (SD range, 0.55-1.17). All item scores encompassed the entire 1 to 4 range. We recommend that 4 items be removed because of low item-item score correlations (r < 0.30). On the basis of the remaining 16 items, 88{\%} of the variance was explained by 2 factors whose Cronbach's α coefficients were.90 and.85. However, items lacked conceptual alignment with previously published factor structures. Conclusion Using a large, diverse sample of European and North American participants, the reduced 16-item QLQ-CIPN20 is sensitive and internally consistent. However, factor analysis results revealed an unstable factor structure. Implications for Practice The use of a reliable, valid, and sensitive criterion-standard QLQ-CIPN20 variant in clinical practice settings could improve function, quality of life, and CIPN symptom control by facilitating patient reporting and thereby clinician awareness of this underrecognized consequence of cancer therapy.",
keywords = "Chemotherapy-induced peripheral neuropathy (CIPN), QLQ-CIPN20, Reliability, Sensitivity, Validity",
author = "Smith, {Ellen M.Lavoie} and Tanima Banerjee and Yang, {James J.} and Bridges, {Celia M.} and Paola Alberti and Sloan, {Jeff A} and Loprinzi, {Charles Lawrence}",
year = "2019",
month = "5",
day = "1",
doi = "10.1097/NCC.0000000000000596",
language = "English (US)",
volume = "42",
pages = "179--189",
journal = "Cancer Nursing",
issn = "0162-220X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data

AU - Smith, Ellen M.Lavoie

AU - Banerjee, Tanima

AU - Yang, James J.

AU - Bridges, Celia M.

AU - Alberti, Paola

AU - Sloan, Jeff A

AU - Loprinzi, Charles Lawrence

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Background No criterion-standard patient-reported outcome measure of chemotherapy-induced peripheral neuropathy (CIPN) exists. Objectives The aims of this study were to reevaluate the sensitivity, reliability, and validity of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN (QLQ-CIPN20) measure and suggest possible revisions that could strengthen it. Methods Cross-sectional QLQ-CIPN20 data from 8 European countries (n = 271) were pooled with data from 4 North American multisite CIPN intervention trials (n = 884). The combined sample (N = 1155) included patients with varied cancer diagnoses who had received neurotoxic chemotherapy. Item score ranges, Cronbach's α, and exploratory factor analysis were used to evaluate sensitivity, internal consistency, and structural validity. Results Individual item mean scores ranged from 1.21 to 2.34 (SD range, 0.55-1.17). All item scores encompassed the entire 1 to 4 range. We recommend that 4 items be removed because of low item-item score correlations (r < 0.30). On the basis of the remaining 16 items, 88% of the variance was explained by 2 factors whose Cronbach's α coefficients were.90 and.85. However, items lacked conceptual alignment with previously published factor structures. Conclusion Using a large, diverse sample of European and North American participants, the reduced 16-item QLQ-CIPN20 is sensitive and internally consistent. However, factor analysis results revealed an unstable factor structure. Implications for Practice The use of a reliable, valid, and sensitive criterion-standard QLQ-CIPN20 variant in clinical practice settings could improve function, quality of life, and CIPN symptom control by facilitating patient reporting and thereby clinician awareness of this underrecognized consequence of cancer therapy.

AB - Background No criterion-standard patient-reported outcome measure of chemotherapy-induced peripheral neuropathy (CIPN) exists. Objectives The aims of this study were to reevaluate the sensitivity, reliability, and validity of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN (QLQ-CIPN20) measure and suggest possible revisions that could strengthen it. Methods Cross-sectional QLQ-CIPN20 data from 8 European countries (n = 271) were pooled with data from 4 North American multisite CIPN intervention trials (n = 884). The combined sample (N = 1155) included patients with varied cancer diagnoses who had received neurotoxic chemotherapy. Item score ranges, Cronbach's α, and exploratory factor analysis were used to evaluate sensitivity, internal consistency, and structural validity. Results Individual item mean scores ranged from 1.21 to 2.34 (SD range, 0.55-1.17). All item scores encompassed the entire 1 to 4 range. We recommend that 4 items be removed because of low item-item score correlations (r < 0.30). On the basis of the remaining 16 items, 88% of the variance was explained by 2 factors whose Cronbach's α coefficients were.90 and.85. However, items lacked conceptual alignment with previously published factor structures. Conclusion Using a large, diverse sample of European and North American participants, the reduced 16-item QLQ-CIPN20 is sensitive and internally consistent. However, factor analysis results revealed an unstable factor structure. Implications for Practice The use of a reliable, valid, and sensitive criterion-standard QLQ-CIPN20 variant in clinical practice settings could improve function, quality of life, and CIPN symptom control by facilitating patient reporting and thereby clinician awareness of this underrecognized consequence of cancer therapy.

KW - Chemotherapy-induced peripheral neuropathy (CIPN)

KW - QLQ-CIPN20

KW - Reliability

KW - Sensitivity

KW - Validity

UR - http://www.scopus.com/inward/record.url?scp=85056906162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056906162&partnerID=8YFLogxK

U2 - 10.1097/NCC.0000000000000596

DO - 10.1097/NCC.0000000000000596

M3 - Article

VL - 42

SP - 179

EP - 189

JO - Cancer Nursing

JF - Cancer Nursing

SN - 0162-220X

IS - 3

ER -